Patients must not have known central nervous system metastasis or a history of central nervous system (CNS) metastases; patients with leptomeningeal disease are not eligible
Subjects with inactive central nervous system (CNS) metastasis are eligible..
Active, untreated central nervous system (CNS) metastasis
History of central nervous system metastasis
Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
Have known central nervous system malignancy or metastasis.
Symptomatic central nervous system (CNS) malignancy or metastasis.
Patient with a tumor metastasis in the central nervous system
Have symptomatic central nervous system malignancy or metastasis.
Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)
Have symptomatic central nervous system (CNS) malignancy or metastasis.
Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
Symptomatic central nervous system metastasis (e.g., patients requiring increasing doses of steroids)
Have symptomatic central nervous system (CNS) malignancy (with the exception of medulloblastoma) or metastasis (screening not required).
Documented central nervous system metastases or liver metastasis
Central nervous system (CNS) metastasis.
Patients with history of prior central nervous system (CNS) metastasis must have been treated, must be asymptomatic, and must not have any of the following at the time of enrollment:
Uncontrolled central nervous system (CNS) metastasis; patients with CNS metastasis can be eligible if definitively treated with radiotherapy or surgery
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
Have known central nervous system malignancy or metastasis.
Central nervous system (CNS) metastasis, endometrial leiomyosarcoma, or endometrial stromal sarcoma.
Central nervous system (CNS) metastasis
About to undergo palliative radiation for a symptomatic central nervous system (CNS) metastasis
Central nervous system (CNS) metastasis
Documented central nervous system metastases or liver metastasis
Active (symptomatic) central nervous system (CNS) metastasis.
Presence of untreated and/or symptomatic central nervous system (CNS) metastasis
History of asymptomatic or symptomatic central nervous system (CNS) metastasis
Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
Known metastasis to the central nervous system
Known metastasis or symptoms of metastasis to the central nervous system
Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
History of central nervous system (CNS) metastasis.
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
Symptomatic central nervous system (CNS) metastasis.
Patients with known metastasis of malignant plasma cells to the central nervous system (if not suspected no specific testing is required)
Symptomatic brain metastasis or uncontrolled central nervous system (CNS) metastasis will not be permitted
Known history of central nervous system metastasis
Has active central nervous system (CNS) or leptomeningeal metastasis
Have symptomatic central nervous system metastasis. Screening of asymptomatic participants is not required for enrollment.
Central nervous system metastasis
Has a history of known central nervous system metastasis
Have known central nervous system metastasis or primary tumor (Part A). Previously-treated, CNS metastasis is permitted in Part B. CNS metastasis must be small, discrete metastasis; stable for at least 30 days without the need for concomitant prednisone for symptom management. No leptomeningeal disease is allowed. Is receiving therapeutic doses of corticosteroids (>20 mg prednisone daily or equivalent);
Central nervous system (CNS) metastasis.
Have the presence of unstable central nervous system (CNS) metastasis.
Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).
Active or untreated central nervous system (CNS) metastasis
Have clinical evidence or a history of central nervous system (CNS) metastasis
Known untreated central nervous system (CNS) metastasis
Symptomatic Central Nervous System (CNS) metastasis
Parts A, B, D and E: Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
History of central nervous system metastasis.
Central nervous system (CNS) metastasis
Have clinical evidence or history of central nervous system metastasis.
Symptomatic central nervous system (CNS) malignancy or metastasis.
Have clinical evidence or history of central nervous system metastasis
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
History of central nervous system (CNS) metastasis that are untreated or not stable
Clinically unstable central nervous system (CNS) metastasis
Clinical evidence of central nervous system (CNS) metastasis.
Have malignancy or metastasis of the central nervous system
Presence or history of central nervous system metastasis (including brain)
For Dose Escalation (Part A): Have central nervous system (CNS) malignancy or metastasis
Known central nervous system metastasis
Patients with history of central nervous system (CNS) metastasis may not be enrolled on the study, unless control has been achieved with either radiation or surgical resection at least 3 months prior to enrollment on study
Known central nervous system metastasis that is unstable within the last 2 months
Have active central nervous system (CNS) metastasis
Central nervous system metastasis
Patients with known central nervous system metastasis are not eligible
Symptomatic central nervous system disease, malignancy, or metastasis
Subjects with known central nervous system (CNS) disease are not eligible, except for those subjects with treated brain metastasis.
Evidence of central nervous system metastasis
Known untreated central nervous system (CNS) metastasis
Known central nervous system (CNS) disease except for treated brain metastasis
Evidence of central nervous system (CNS) metastasis who have not received prior definitive therapy for their lesions.
Current uncontrolled central nervous system (CNS) metastasis or malignant brain tumors
Patients with Central Nervous System (CNS) metastasis which are: symptomatic or require treatment for symptom control and/or growing
Stage IV patients are considered provided they have a single non-central nervous system (CNS) metastasis (that is amenable to treatment with radiation therapy)
Known central nervous system metastasis
Symptomatic central nervous system malignancy or metastasis (screening not required).
Have symptomatic central nervous system (CNS) malignancy or metastasis
Patients with history of central nervous system (CNS) metastasis, unless control has been achieved with either radiation or surgical resection at least 3 months prior to enrollment on study
Active untreated central nervous system (CNS) metastasis
Known central nervous system metastasis
Known untreated central nervous system (CNS) metastasis; patients with CNS metastasis will be allowed on study once treated
Evidence of central nervous system metastasis and have not received prior definitive therapy for their lesions.
Known brain metastasis or primary central nervous system (CNS) malignancy
Patient must not have untreated or symptomatic central nervous system (CNS) metastasis
Known central nervous system (CNS) metastasis; once CNS metastasis have been treated these patients may participate if they are otherwise good trial candidates
Have symptomatic central nervous system (CNS) malignancy or metastasis.
Subjects with symptomatic brain metastasis or central nervous system (CNS) disease
Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
